Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct

Abstract

MIB-1, and the argyrophilic nucleolar organizer regions (AgNOR) and examined the relationships among them in carcinoma of the extrahepatic bile duct (EHBD). Shin-ichi RESULTS. MIB-1 and AgNOR were closely associated with lymph node metastasisIwate Medical University, Morioka, Japan.(P õ 0.01). The cumulative survival rate for patients with a low MIB-1 labeling index (LI) (õ29%) was significantly better than that for patients with a high MIB-2 Division of Pathology, Central Clinical Laboratory, School of Medicine, Iwate Medical Univer-1 LI (¢29%) in cases of EHBD carcinoma (P õ 0.05), but MIB-1 was not an indepensity, Morioka, Japan. dent prognostic factor in multivariate analysis. The results indicated that AgNOR and p53 overexpression had no prognostic value. The authors detected p53 in 24 of the 54 EHBD carcinomas (44.4%). There was a significant correlation between MIB-1 and AgNOR (P õ 0.01). The authors found that neither MIB-1 nor AgNOR correlated with p53 overexpression. CONCLUSIONS. MIB-1 and

Papillary adenoma of the distal common bile duct

“…There was no invasive growth microscopically, but positive immunoreactivity for MIB-1 and p53 suggested the malignant potential of the lesion. Suto et al 27 reported that alterations of p53 may be a rather early event in the progression of extrahepatic biliary carcinoma, because accumulation of changes is observed in early cancer without metastasis. Finally, we diagnosed this lesion as a papillary adenoma with focal severe atypia.…”

p53 Status and Its Prognostic Role in Extrahepatic Bile Duct Cancer: A Meta-Analysis of Published Studies

“…As a result, according to the inclusion and exclusion criteria, there were ten eligible studies published from 1994 to 2006. There were two studies, both reported by Suto et al, based on the same patient cohort [15,24]. So we gave up the study whose number of patients is smaller [24].…”

“…Two studies were excluded because we could not extract the data of p53 and its impact on survival [25,26]. Finally, a total of seven independent studies were included in this meta-analysis [11][12][13][14][15][16][17].…”

“…Five studies have investigated the relationship between routine clinicopathological parameters and p53 level [15,16,[27][28][29]. As shown in Table 2, two of these five studies described a significant correlation between venous invasion and high level of p53 [15,27].…”

“…In the past two decades, only limited studies have been published on the prognostic significance of the p53 status in EBDC. Moreover, estimates of the prognostic values differed widely among studies, precluding a systematic correlation between p53 status and prognosis [11][12][13][14][15][16][17].…”